Company profile for BioNTech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioNTech SE is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all of the building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen ...
BioNTech SE is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all of the building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
An der Goldgrube 12 D-55131 Mainz
Telephone
Telephone
+49-6131-9084-0
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/fda/fda-plans-black-box-warning-for-covid-19-vaccines-report

BIOSPACE
12 Dec 2025

https://www.indianpharmapost.com/clinical-trials/biontech-and-bristol-myers-squibb-report-punchy-early-results-for-experimental-tnbc-therapy-18517

INDPHARMAPOST
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/03/3198964/0/en/BioNTech-Achieves-Minimum-Condition-in-CureVac-Exchange-Offer.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197250/0/en/BioNTX-Concludes-Landmark-iC-2025-Summit-Announces-2026-Summit-in-Arlington-Texas.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/26/3195060/0/en/BioNTech-Shares-Progress-on-Exchange-Offer-for-CureVac-Shares-and-Highlights-December-3-2025-at-9-00-a-m-Eastern-Time-Expiration.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/10/28/3175301/0/en/BioNTech-to-Host-Innovation-Series-R-D-Day-on-November-11-2025.html

GLOBENEWSWIRE
28 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty